Star Equity (STRR) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	May 07, 2023
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-35947
Entity Registrant Name	Star Equity Holdings, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-0145723
Entity Address, Address Line One	53 Forest Ave., Suite 101,
Entity Address, City or Town	Old Greenwich
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06870
City Area Code	203
Local Phone Number	489-9500
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Outstanding		15,196,090
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Central Index Key	0000707388
Common Stock, par value $0.0001 per share
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	STRR
Security Exchange Name	NASDAQ
Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share
Entity Information [Line Items]
Title of 12(b) Security	Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share
Trading Symbol	STRRP
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Total revenues	$ 25,705	$ 25,049
Cost of revenues:
Total cost of revenues	18,112	20,386
Gross profit	7,593	4,663
Operating expenses:
Selling, general and administrative	6,433	6,788
Amortization of intangible assets	430	430
Total operating expenses	6,863	7,218
Income (loss) from operations	730	(2,555)
Other income (expense):
Other income (expense), net	(100)	(6)
Interest expense, net	(195)	(190)
Total other income (expense), net	(295)	(196)
Income (loss) before income taxes	435	(2,751)
Income tax benefit (provision)	0	(950)
Net income (loss)	435	(3,701)
Deemed dividend on Series A perpetual preferred stock	(479)	(479)
Net income (loss) attributable to common shareholders	(44)	(4,180)
Net income (loss) attributable to common shareholders	$ (44)	$ (4,180)
Net income (loss) per share
Net income (loss) per share - basic (in usd per share)	$ 0.03	$ (0.29)
Net income (loss) per share - diluted (in usd per share)	0.03	(0.29)
Net income (loss) per share, attributable to common shareholders— basic (in usd per share)	0	(0.33)
Net income (loss) per share, attributable to common shareholders— diluted (in usd per share)	$ 0	$ (0.33)
Weighted-average common shares outstanding—basic (in shares)	15,516	12,669
Weighted-average common shares outstanding - diluted (in shares)	15,656	12,669
Dividends declared per share of Series A perpetual preferred stock (in usd per share)	$ 0.25	$ 0.25
Healthcare
Revenues:
Total revenues	$ 13,359	$ 13,418
Cost of revenues:
Total cost of revenues	10,032	10,242
Construction
Revenues:
Total revenues	12,346	11,631
Cost of revenues:
Total cost of revenues	8,017	10,045
Investments
Cost of revenues:
Total cost of revenues	$ 63	$ 99

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,655	$ 4,665
Restricted cash	141	142
Investments in equity securities	3,577	3,490
Accounts receivable, net of allowances of $500 and $714, respectively	15,000	17,756
Inventories, net	10,043	10,627
Other current assets	2,239	2,587
Total current assets	36,655	39,267
Property and equipment, net	8,102	8,348
Operating lease right-of-use assets, net	4,040	4,482
Intangible assets, net	12,922	13,352
Goodwill	6,046	6,046
Other assets	1,736	1,807
Total assets	69,501	73,302
Current liabilities:
Accounts payable	4,125	3,430
Accrued liabilities	2,665	3,137
Accrued compensation	4,025	3,701
Accrued warranty	290	291
Lumber derivative contracts	62	104
Deferred revenue	2,926	3,376
Short-term debt	8,394	11,682
Operating lease liabilities	1,371	1,427
Finance lease liabilities	348	397
Total current liabilities	24,206	27,545
Deferred tax liabilities	176	176
Operating lease liabilities, net of current portion	2,749	3,141
Finance lease liabilities, net of current portion	300	386
Deferred Revenue, net of current portion	257	299
Total liabilities	27,688	31,547
Commitments and contingencies (Note 8)
Stockholders’ Equity:
Common stock, $0.0001 par value: 50,000,000 shares authorized, respectively; 15,192,753 and 15,177,919 shares issued and outstanding (net of treasury shares) at March 31, 2023 and December 31, 2022, respectively	1	1
Treasury stock, at cost; 258,849 shares at March 31, 2023 and December 31, 2022, respectively	(5,728)	(5,728)
Additional paid-in capital	161,338	161,715
Accumulated deficit	(132,786)	(133,221)
Total stockholders’ equity	41,813	41,755
Total liabilities and stockholders’ equity	69,501	73,302
Series A Preferred Stock
Stockholders’ Equity:
Preferred stock, $0.0001 par value	18,988	18,988
Series C Preferred Stock
Stockholders’ Equity:
Preferred stock, $0.0001 par value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable, allowance for credit loss, current	$ 500,000	$ 714,000
Liquidation preference (in usd per share)	$ 10
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)		50,000,000
Common stock, issued (in shares)	15,192,753	15,177,919
Common stock, outstanding (in shares)	15,192,753	15,177,919
Treasury stock (in shares)	258,849	258,849
Series A Preferred Stock
Preferred stock, par value (in usd per share)	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000
Preferred stock, liquidation preference shares authorized (in shares)	8,000,000
Liquidation preference (in usd per share)	$ 10
Preferred stock, shares issued (in shares)	1,915,637
Preferred stock, outstanding (in shares)	1,915,637
Preferred stock, liquidation preference	$ 18,988,390
Series C Preferred Stock
Preferred stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	25,000	25,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities
Net (loss) income	$ 435	$ (3,701)
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:
Depreciation of property and equipment	414	471
Amortization of intangible assets	430	430
Non-cash lease expense	349	199
Provision for bad debt, net	28	300
Stock-based compensation	102	144
Amortization of loan issuance costs	28	37
(Gain) loss on sale of assets	(35)	(96)
Deferred income taxes	0	926
Unrealized (gain) loss of equity securities and lumber derivatives	(45)	584
Changes in operating assets and liabilities:
Accounts receivable	2,729	(397)
Inventories	584	(1,762)
Other assets	413	144
Accounts payable	694	919
Accrued compensation	323	142
Deferred revenue and billings in excess of costs and estimated profit	(449)	220
Operating lease liabilities	(357)	(185)
Other liabilities	(511)	989
Net cash provided (used) by operating activities	5,132	(636)
Investing activities
Purchases of property and equipment	(136)	(366)
Proceeds from sale of property and equipment	3	112
Purchases of equity securities	(85)	(1,070)
Proceeds from sales of equity securities	0	14
Net cash provided (used) by investing activities	(218)	(1,310)
Financing activities
Proceeds from borrowings	23,299	25,186
Repayment of debt	(26,606)	(24,748)
Proceeds from the sale of common stock, warrants, and exercise of over allotment options	0	13,198
Fees paid on issuance of common stock	0	(450)
Taxes paid related to net share settlement of equity awards	0	(3)
Repayment of obligations under finance leases	(139)	(154)
Preferred stock dividends paid	(479)	(479)
Net cash provided (used) by financing activities	(3,925)	12,550
Net increase in cash, cash equivalents, and restricted cash	989	10,604
Cash, cash equivalents, and restricted cash at beginning of period	4,807	4,816
Cash, cash equivalents, and restricted cash at end of period	5,796	15,420
Reconciliation of cash, cash equivalents, and restricted cash at end of year
Cash and cash equivalents	5,655	15,035
Restricted cash	141	385
Cash, cash equivalents, and restricted cash at end of period	5,796	15,420
Supplemental Information
Cash paid during the year for interest	328	0
Cash paid during the year for income taxes	$ 0	$ 0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Perpetual Preferred Stock	Common stock	Treasury Stock	Additional paid-in capital	Accumulated deficit
Perpetual redeemable preferred stock, beginning balance (in shares) at Dec. 31, 2021	1,916,000
Perpetual redeemable preferred stock, beginning balance at Dec. 31, 2021	$ 18,988
Increase (Decrease) in Temporary Equity [Roll Forward]
Accrued dividend on redeemable preferred stock	479
Preferred stock dividends paid	$ (479)
Perpetual redeemable preferred stock, ending balance (in shares) at Mar. 31, 2022	1,916,000
Perpetual redeemable preferred stock, ending balance at Mar. 31, 2022	$ 18,988
Preferred stock, beginning balance (in shares) at Dec. 31, 2021		0
Common stock, beginning balance (in shares) at Dec. 31, 2021			5,805,000
Beginning balance at Dec. 31, 2021	16,754	$ 0	$ 0	$ (5,728)	$ 150,451	$ (127,969)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	144				144
Shares issued under stock incentive plans, net of shares withheld for employee taxes (in shares)			49,000
Shares issued under stock incentive plans, net of shares withheld for employee taxes	(3)				(3)
Dividends to holders of preferred stock ($0.25 per share)	(479)				(479)
Equity issuance costs	(450)				(450)
Proceeds from the sale of common stock, warrants, and exercise of over allotment options (in shares)			9,175,000
Proceeds from the sale of common stock, warrants, and exercise of over allotment options	13,198		$ 1		13,197
Net income (loss)	(3,701)					(3,701)
Preferred stock, ending balance (in shares) at Mar. 31, 2022		0
Common stock, ending balance (in shares) at Mar. 31, 2022			15,029,000
Ending balance at Mar. 31, 2022	$ 25,463	$ 0	$ 1	(5,728)	162,860	(131,670)
Perpetual redeemable preferred stock, beginning balance (in shares) at Dec. 31, 2022	0
Perpetual redeemable preferred stock, beginning balance at Dec. 31, 2022	$ 0
Perpetual redeemable preferred stock, ending balance (in shares) at Mar. 31, 2023	0
Perpetual redeemable preferred stock, ending balance at Mar. 31, 2023	$ 0
Preferred stock, beginning balance (in shares) at Dec. 31, 2022		1,916,000
Common stock, beginning balance (in shares) at Dec. 31, 2022	15,177,919		15,178,000
Beginning balance at Dec. 31, 2022	$ 41,755	$ 18,988	$ 1	(5,728)	161,715	(133,221)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	102				102
Shares issued under stock incentive plans, net of shares withheld for employee taxes (in shares)			15,000
Shares issued under stock incentive plans, net of shares withheld for employee taxes	0				0
Dividends to holders of preferred stock ($0.25 per share)	(479)				(479)
Net income (loss)	$ 435					435
Preferred stock, ending balance (in shares) at Mar. 31, 2023		1,916,000
Common stock, ending balance (in shares) at Mar. 31, 2023	15,192,753		15,193,000
Ending balance at Mar. 31, 2023	$ 41,813	$ 18,988	$ 1	$ (5,728)	$ 161,338	$ (132,786)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUIT YAND STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares		3 Months Ended
	Feb. 17, 2023	Mar. 31, 2023	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Dividends declared per Series A perpetual preferred stock (in usd per share)	$ 0.25	$ 0.25	$ 0.25

Basis of Presentation and Signi

Basis of Presentation and Significant Policies	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Policies	Basis of Presentation and Significant Policies Basis of Presentation The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (the “SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally Accepted Accounting Principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed Consolidated Balance Sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2022, filed with the SEC on Form 10-K on March 15, 2023, include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows, and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. The Company Star Equity Holdings, Inc. (“Star Equity,” the “Company,” “we,” or “our”) is a multi-industry diversified holding company with two divisions: Construction and Investments. The Company previously had a Healthcare division which was sold on May 4, 2023, as further described in Note 16. “Subsequent Events.” Our common stock and preferred stock are listed on the NASDAQ Global Market exchange as “STRR” and “STRRP”, respectively. Liquidity and Management’s Plan At December 31, 2022, we identified certain conditions and events which in the aggregate required management to perform an assessment of the Company’s ability to continue as a going concern for one year from the financial statements issuance date. Management’s analysis indicated that there is no substantial doubt regarding the entity’s ability to continue as a going concern for one year from the financial statements issuance date. For the quarter ended March 31, 2023 we achieved net income of $0.4 million and positive cash flow from operations of $5.1 million. As of March 31, 2023, cash and cash equivalents amounted to $5.7 million and our investments in publicly traded companies amounted to $3.6 million. Additionally, as further discussed in Note 16. “Subsequent Events”, we received approximately $27 million in cash from the sale of our Healthcare business on May 4, 2023 and paid the full outstanding balance owed under the Webster Loan Agreement (as defined herein). In addition, we have given notice to eCapital (as defined in Note 7. “Debt”) that we will not be renewing our credit facilities with eCapital upon their June 30, 2023 expiration. We have projected positive cash flow generation for the next 12 months from the issuance date of these financial statements. Our forecasts are dependent on our ability to maintain margins at our operating companies which includes achieving levels of booked orders, minimizing expenses and achieving certain free cash flow benchmarks. We have begun to explore certain financing arrangements, including sale and leaseback opportunities, subsequent to the date of these financial statements.There can be no assurance that the Company will enter into such a financing arrangement or as to the terms of any such financing arrangement. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and disclosures made in the accompanying notes to the condensed consolidated financial statements. Significant estimates and judgments include those related to inventory, revenue recognition, lease accounting, fair value measurements (including contingent considerations), litigation and contingent liabilities, variable interest entities, intangible assets and goodwill valuations, equity classification and transactions, and income taxes. Actual results could materially differ from those estimates. Concentration of Credit Risk Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents and accounts receivable. We limit our exposure to credit loss by generally placing cash in high credit quality financial institutions. Cash balances are maintained primarily at major financial institutions in the United States, a portion of which exceed the regulatory limit of $250,000 insured by the Federal Deposit Insurance Corporation (FDIC). We have not experienced any credit losses associated with our cash balances. Additionally, we have established guidelines regarding diversification of our investments and their maturities, which are designed to maintain principal and maximize liquidity. As of March 31, 2023 we have $4.4 million of cash in excess of FDIC insured limits Mezzanine Equity Pursuant to the Certificate of Designations, Rights and Preferences of 10% Series A Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock”) of Star Equity (formerly Digirad Corporation) (the “Certificate of Designations”), upon a Change of Control Triggering Event, as defined in the Certificate of Designations, holders of the Series A Preferred Stock had the ability to require the Company to redeem the Series A Preferred Stock at a price of $10.00 per share, plus any accumulated and unpaid dividends (a “Change of Control Redemption”). As this redemption feature of the shares was not solely within the control of the Company, the Series A Preferred Stock did not qualify as permanent equity and was classified as mezzanine or temporary equity. The Series A Preferred Stock was not redeemable and it was not probable that our Series A Preferred Stock would become redeemable as of June 2, 2022. Therefore, we were not previously required to accrete the Series A Preferred Stock to its redemption value. On June 2, 2022, the Certificate of Designations was amended to include a “Special Optional Redemption Right” at the Company’s discretion and to extinguish the option of preferred stockholders to redeem preferred shares upon a Change of Control Triggering Event, as defined in the Certificate of Designations, as amended. As the redemption features of the Series A Preferred Stock are now solely within the control of the Company, the Series A Preferred Stock qualifies as permanent equity and has been reclassified to permanent equity effective June 2, 2022. In addition to the foregoing redemption features, the Certificate of Designations also provides that we may redeem (at our option, in whole or in part) the Series A Preferred Stock following the fifth anniversary of issuance of the Series A Preferred Stock, at a cash redemption price of $10.00 per share, plus any accumulated and unpaid dividends. Refer to preferred stock dividends discussed in Note 12. Perpetual Preferred Stock. New Accounting Standards To Be Adopted No new accounting standards were issued in the quarter ended March 31, 2023 that are expected to have a material impact on our financial statements.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Disaggregation of Revenue During the first quarter of 2023 and until May 4, 2023, the Company had three reporting segments (see Note 10. “Segments”) and has five major goods and service lines which are either transferred over time or at a point in time. The following tables present our revenues for the three months ended March 31, 2023 and 2022, disaggregated by major source (in thousands): Three Months Ended March 31, 2023 Healthcare Construction Total Major Goods/Service Lines Mobile Imaging (1) $ 10,323 $ — $ 10,323 Camera Sales 952 — 952 Camera Support 1,899 — 1,899 Healthcare Revenue from Contracts with Customers 13,174 — 13,174 Lease Income 185 — 185 Construction Revenue from Contracts with Customers — 12,346 12,346 Total Revenues $ 13,359 $ 12,346 $ 25,705 Timing of Revenue Recognition Services and goods transferred over time $ 10,545 $ — $ 10,545 Services and goods transferred at a point in time 2,814 12,346 15,160 Total Revenues $ 13,359 $ 12,346 $ 25,705 Three Months Ended March 31, 2022 Healthcare Construction Total Major Goods/Service Lines Mobile Imaging (1) $ 10,518 $ — $ 10,518 Camera Sales 1,132 — 1,132 Camera Support 1,679 — 1,679 Healthcare Revenue from Contracts with Customers 13,329 — 13,329 Lease Income 89 — 89 Construction Revenue from Contracts with Customers — 11,631 11,631 Total Revenues $ 13,418 $ 11,631 $ 25,049 Timing of Revenue Recognition Services and goods transferred over time $ 10,854 $ 1,897 $ 12,751 Services and goods transferred at a point in time 2,564 9,734 12,298 Total Revenues $ 13,418 $ 11,631 $ 25,049 Deferred Revenue Changes in deferred revenue for the three months ended March 31, 2023, is as follows (in thousands): Balance at December 31, 2022 $ 3,675 Revenue recognized that was included in balance at beginning of the year (1,790) Deferred revenue, net, related to contracts entered into during the year 1,298 Balance at March 31, 2023 $ 3,183

Basic and Diluted Net Income (L

Basic and Diluted Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share We present net income (loss) per share attributable to common stockholders in conformity with the two-class method required for participating securities, as the warrants are considered participating securities. We have not allocated net income (loss) attributable to common stockholders to warrants because the holders of our warrants are not contractually obligated to share in our income (loss). Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share attributable to common stockholders is calculated to give effect to all potential shares of common stock, including common stock issuable upon exercise of warrants, stock options, and restricted stock units (“RSUs”). In periods for which there is a net loss, diluted loss per common share is equal to basic loss per common share, since the effect of including any common stock equivalents would be antidilutive. The following table sets forth the reconciliation of shares used to compute basic and diluted net income (loss) per share for the periods indicated (in thousands): Three Months Ended March 31, 2023 2022 Numerator: Net income (loss) 435 (3,701) Deemed dividend on Series A perpetual preferred stock (479) (479) Net income (loss) attributable to common shareholders $ (44) $ (4,180) Denominator: Weighted average common shares outstanding 15,191 12,434 Weighted average prefunded warrants outstanding 325 235 Weighted average shares outstanding - basic 15,516 12,669 Dilutive potential common shares: Restricted stock units 140 — Weighted average shares outstanding - diluted 15,656 12,669 Net income (loss) per share Basic $ 0.03 $ (0.29) Diluted $ 0.03 $ (0.29) Net income (loss) per share, attributable to common shareholders Basic $ — $ (0.33) Diluted $ — $ (0.33) *Earnings per share may not add due to rounding Antidilutive common stock equivalents are excluded from the computation of diluted income (loss) per share. The computation of diluted earnings per share excludes stock options, RSUs, and stock warrants that are anti-dilutive. The following common stock equivalents were anti-dilutive (in thousands): Three Months Ended March 31, 2023 2022 Stock options 2 6 Restricted stock units 80 271 Stock warrants 11,865 9,361 Total 11,947 9,638

Supplementary Balance Sheet Inf

Supplementary Balance Sheet Information	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Supplementary Balance Sheet Information	Supplementary Balance Sheet Information Inventories The components of inventories are as follows (in thousands): March 31, 2023 December 31, 2022 Raw materials $ 5,609 $ 6,330 Work-in-process 2,772 2,567 Finished goods 1,886 1,946 Total inventories 10,267 10,843 Less reserve for excess and obsolete inventories (224) (216) Total inventories, net $ 10,043 $ 10,627 Property and Equipment Property and equipment consist of the following (in thousands): March 31, 2023 December 31, 2022 Land $ 805 $ 805 Buildings and leasehold improvements 4,843 4,843 Machinery and equipment 24,398 24,648 Computer hardware and software 2,486 2,465 Gross property and equipment 32,532 32,761 Accumulated depreciation (24,430) (24,413) Total property and equipment, net $ 8,102 $ 8,348 As of March 31, 2023, the non-operating land and buildings, held for investments, had a carry value of $1.9 million and was included within property and equipment on the condensed Consolidated Balance Sheet. Warranty Reserves In our Healthcare division, we generally provide a 12-month assurance warranty on our gamma cameras. We accrue the estimated cost of this warranty at the time revenue is recorded and charge warranty expense to product and product-related cost of revenues. Warranty reserves are established based on historical experience with failure rates and repair costs and the number of systems covered by warranty. Warranty reserves are depleted as gamma cameras are repaired. The costs consist principally of materials, personnel, overhead, and transportation. We review warranty reserves quarterly and make adjustments, as necessary. Within our Construction division, KBS Builders, Inc. (“KBS”) provides a limited assurance warranty on its residential homes that covers substantial defects in materials or workmanship for a period of 12 months after delivery to the owner. EdgeBuilder, Inc. (“EdgeBuilder”) provides a limited warranty on the sale of its wood foundation products that covers leaks resulting from defects in workmanship for a period of twenty-five years. Estimated warranty costs are accrued in the period that the related revenue is recognized. The activities related to our warranty reserve for the period ended March 31, 2023 and year ended December 31, 2022 are as follows (in thousands): March 31, 2023 December 31, 2022 Balance at the beginning of year $ 291 $ 569 Charges to cost of revenues 85 177 Applied to liability (86) (455) Balance at the end of period $ 290 $ 291

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	Leases Lessee We have operating and finance leases for corporate offices, vehicles, and certain equipment. Our leases have remaining lease terms of 1 year to 10 years, some of which include options to extend the leases and some of which include options to terminate the leases within 1 year. Operating leases and finance leases are included separately in the condensed Consolidated Balance Sheets. The components of lease expense are as follows (in thousands): Three Months Ended March 31, 2023 2022 Operating lease cost $ 390 $ 396 Finance lease cost: Amortization of finance lease assets $ 116 $ 123 Interest on finance lease liabilities 11 17 Total finance lease cost $ 127 $ 140 Supplemental cash flow information related to leases from continuing operations was as follows (in thousands): Three Months Ended March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 349 $ 199 Operating cash flows from finance leases $ 11 $ 17 Financing cash flows from finance leases $ 139 $ 157 Right-of-use assets obtained in exchange for lease obligations Operating leases $ — $ 1,229 Supplemental balance sheet information related to leases was as follows (in thousands): March 31, December 31, Weighted average remaining lease term (in years) Operating leases 3.5 3.7 Finance leases 2.1 2.3 Weighted average discount rate Operating leases 4.68 % 4.66 % Finance leases 5.98 % 5.98 % We are committed to making future cash payments on non-cancelable operating leases and finance leases (including interest). The future minimum lease payments due under both non-cancelable operating leases and finance leases having initial or remaining lease terms in excess of one year as of March 31, 2023 were as follows (in thousands): Operating Leases Finance Leases 2023 (excludes the three months ended March 31, 2023) $ 1,146 $ 292 2024 1,392 266 2025 918 103 2026 591 16 2027 155 1 2028 and thereafter 206 — Total future minimum lease payments 4,408 678 Less amounts representing interest 288 30 Present value of lease obligations $ 4,120 $ 648 Lessor
Leases	Leases Lessee We have operating and finance leases for corporate offices, vehicles, and certain equipment. Our leases have remaining lease terms of 1 year to 10 years, some of which include options to extend the leases and some of which include options to terminate the leases within 1 year. Operating leases and finance leases are included separately in the condensed Consolidated Balance Sheets. The components of lease expense are as follows (in thousands): Three Months Ended March 31, 2023 2022 Operating lease cost $ 390 $ 396 Finance lease cost: Amortization of finance lease assets $ 116 $ 123 Interest on finance lease liabilities 11 17 Total finance lease cost $ 127 $ 140 Supplemental cash flow information related to leases from continuing operations was as follows (in thousands): Three Months Ended March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 349 $ 199 Operating cash flows from finance leases $ 11 $ 17 Financing cash flows from finance leases $ 139 $ 157 Right-of-use assets obtained in exchange for lease obligations Operating leases $ — $ 1,229 Supplemental balance sheet information related to leases was as follows (in thousands): March 31, December 31, Weighted average remaining lease term (in years) Operating leases 3.5 3.7 Finance leases 2.1 2.3 Weighted average discount rate Operating leases 4.68 % 4.66 % Finance leases 5.98 % 5.98 % We are committed to making future cash payments on non-cancelable operating leases and finance leases (including interest). The future minimum lease payments due under both non-cancelable operating leases and finance leases having initial or remaining lease terms in excess of one year as of March 31, 2023 were as follows (in thousands): Operating Leases Finance Leases 2023 (excludes the three months ended March 31, 2023) $ 1,146 $ 292 2024 1,392 266 2025 918 103 2026 591 16 2027 155 1 2028 and thereafter 206 — Total future minimum lease payments 4,408 678 Less amounts representing interest 288 30 Present value of lease obligations $ 4,120 $ 648 Lessor

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis The Financial Accounting Standards Board’s authoritative guidance for fair value measurements establishes a three-level hierarchy based upon the inputs to the valuation model of an asset or liability. Level 1 inputs are quoted prices in active markets for identical assets; Level 2 inputs are inputs other than quoted prices that are significant and observable; and Level 3 inputs are significant unobservable inputs to be used in situations where markets do not exist or illiquid. The following table presents information about our financial assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2023 and December 31, 2022 (in thousands): Fair Value as of March 31, 2023 Level 1 Level 2 Level 3 Total Assets (Liabilities): Equity securities $ 3,577 $ — $ — $ 3,577 Lumber derivative contracts (62) — — (62) Total $ 3,515 $ — $ — $ 3,515 Fair Value as of December 31, 2022 Level 1 Level 2 Level 3 Total Assets (Liabilities): Equity securities $ 3,490 $ — $ — $ 3,490 Lumber derivative contracts (104) — — (104) Total $ 3,386 $ — $ — $ 3,386 The investment in equity securities consists of common stock of publicly traded companies. The fair value of these securities is based on the closing prices observed on March 31, 2023 and December 31, 2022, respectively, and recorded in Investments in the condensed Consolidated Balance Sheets. During the three months ended March 31, 2023 and 2022, we recorded an unrealized gain of $2 thousand and $92 thousand, respectively, recorded in other (expense) income, net in the condensed Consolidated Statements of Operations. We may enter into lumber derivative contracts in order to protect our gross profit margins from fluctuations caused by volatility in lumber price, recorded within current assets or liabilities in the condensed Consolidated Balance Sheets. For the three months ended March 31, 2023 and 2022, we recorded a net loss of $46 thousand and $0.2 million, respectively, in the cost of goods sold in the condensed Consolidated Statements of Operations. As of March 31, 2023, we had a net long (buying) position of 5,500,000 board feet under 50 lumber derivatives contracts. As of December 31, 2022, we had a net long (buying) position of 550,000 board feet under 5 lumber derivatives contracts. Gains and losses from lumber derivative contracts are recorded in cost of goods sold of the condensed Consolidated Statements of Operations and included the following for the three months ended March 31, 2023 and 2022, respectively: March 31, 2023 March 31, 2022 Unrealized gain (loss) on lumber derivatives $ (43) $ 676 Realized gain (loss) on lumber derivatives 89 (448) Total gain (loss) on lumber derivatives $ 46 $ 228

Debt

Debt	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Debt	Debt A summary of debt as of March 31, 2023 and December 31, 2022 is as follows (dollars in thousands): March 31, 2023 December 31, 2022 Amount Weighted-Average Interest Rate Amount Weighted-Average Interest Rate Revolving Credit Facility - eCapital KBS $ — 10.75% $ — 10.25% Revolving Credit Facility - eCapital EBGL — 10.75% 2,592 10.25% Revolving Credit Facility - Webster 7,685 7.36% 8,299 6.89% Total Short-term Revolving Credit Facilities $ 7,685 7.36% $ 10,891 7.69% eCapital - Star Loan Principal, net $ 709 11.00% $ 791 10.50% Short Term Loan $ 709 11.00% $ 791 10.50% Total Short-term debt $ 8,394 7.67% $ 11,682 7.88% Webster Credit Facility On March 29, 2019, the Company entered into a Loan and Security Agreement (the “Webster Loan Agreement”) by and among certain subsidiaries of the Company, as borrowers (collectively, the “Webster Borrowers”); the Company, as guarantor; and Sterling National Bank (“Sterling”). On February 1, 2022, Sterling became part of Webster Bank, N.A. (“Webster”), and Webster became the successor in interest to the Webster Loan Agreement. The Webster Loan Agreement was also subject to a limited guarantee by Mr. Eberwein, the Executive Chairman of our board of directors. The Webster Loan Agreement was a five-year credit facility maturing in March 2024, with a maximum credit amount of $20.0 million for revolving loans (the “Webster Credit Facility”). In connection with the sale of our Healthcare business on May 4, 2023, we paid off the Webster Credit Facility in full, using the proceeds from the sale. Under the Webster Credit Facility, the Webster Borrowers were able to request the issuance of letters of credit in an aggregate amount not to exceed $0.5 million at any one time outstanding. The borrowings under the Webster Loan Agreement were classified as short-term obligations under GAAP as the agreement contains a subjective acceleration clause and required a lockbox arrangement whereby all receipts within the lockbox are swept daily to reduce borrowings outstanding. As of March 31, 2023, the Company had $0.1 million of letters of credit outstanding and had additional borrowing capacity of $0.5 million under the Webster Credit Facility. At the Webster Borrowers’ option, the Webster Credit Facility bore interest at either (i) a Floating LIBOR Rate, as defined in the Webster Loan Agreement, plus a margin of 2.50% per annum; or (ii) a Fixed LIBOR Rate, as defined in the Webster Loan Agreement, plus a margin of 2.25% per annum. Our floating rate on this facility at March 31, 2023 was 7.36%. The Webster Loan Agreement also provided for unused line fees and restricts the usage of borrowings under the line solely to support the Healthcare businesses, subject to certain limitations. The Webster Credit Facility was secured by the assets of the Digirad Health businesses. Financial covenants required that the Webster Borrowers maintain (a) a Fixed Charge Coverage Ratio as of the last day of a fiscal quarter of not less than 1.25 to 1.0 and (b) a Leverage Ratio as of the last day of such fiscal quarter of no greater than 3.50 to 1.0 . As of March 31, 2023, we believe that we were in compliance with the covenants under the Webster Loan Agreement. eCapital Credit Facilities EBGL EdgeBuilder and Glenbrook Building Supply, Inc. (“Glenbrook” and, together with EdgeBuilder, collectively the “EBGL Borrowers”) are parties to a Loan and Security Agreement (the “EBGL Loan Agreement”) providing the EBGL Borrowers with a credit facility with eCapital Asset Based Lending Corp. formerly known as Gerber Finance, Inc. (“eCapital” for borrowings up to $4.0 million, subject to certain borrowing base limitations (the “EBGL Loan”). As of March 31, 2023, EBGL had additional borrowing capacity of $2.8 million under the facility. Amounts outstanding bear interest, payable monthly, at the prime rate plus 2.75% and payments of outstanding principal are due in full upon maturity. The facility is subject to annual renewal and is currently set to mature on June 30, 2023 or earlier (as amended in the eleventh amendment to the EBGL Loan Agreement). Financial covenants require that EBGL maintain (a) net income (as defined in the EBGL Loan Agreement) at least equal to no less than $0 for the trailing 6-month period ending June 30, 2022 and no less than $1,000,000 for the trailing fiscal year ending December 31, 2022 and (b) a reduced minimum EBITDA (as defined in the EBGL Loan Agreement) to be no less than $0 as of June 30, 2022 and no less than $1,000,000 as of the fiscal year ending December 31, 2022. EBGL was in compliance with the bi-annual financial covenants under the EBGL Loan Agreement measured as of December 31, 2022. KBS KBS is a party to a revolving credit facility with eCapital (“KBS Loan Agreement”). The facility, as amended, provides for borrowings up to $4.0 million, subject to certain borrowing base limitations. As of March 31, 2023, KBS had additional borrowing capacity of $1.0 million under the facility. Amounts outstanding bear interest, payable monthly, at the prime rate plus 2.75% and payments of outstanding principal are due in full upon maturity. The facility is subject to annual renewal and is currently set to mature on June 30, 2023 or earlier (as amended in the Twenty First Amendment of the KBS Loan Agreement). The facility is secured by the assets of KBS and borrowings under the line are restricted for use to finance the operations of KBS. Financial covenants require that KBS maintain (a) net income (as defined in the KBS Loan Agreement) of at least equal to no less than $0 for the trailing 6-month period ending June 30, 2022 and be no less than $500,000 for the trailing fiscal year end and (b) a minimum EBITDA (as defined in the KBS Loan Agreement) no less than $0 as of June 30 and no less than $850,000 as of the fiscal year end. As of December 31, 2022, KBS was in compliance with the bi-annual financial covenants under the KBS Loan Agreement. The eCapital credit facilities contain cross-default provisions and subjective acceleration clauses which may, in the event of a material adverse event, as determined by eCapital, allow eCapital to declare the loans immediately due and payable or increase the interest rate. The facilities are also subject to a guaranty by the Company and the Company is responsible for certain facility and other fees. Borrowings under the eCapital credit facilities are classified as short-term obligations as the agreements contain a subjective acceleration clauses and require a lockbox arrangement whereby all receipts within the lockbox are swept daily to reduce borrowings outstanding. Term Loan We and certain of our Investments subsidiaries (collectively, the “Star Borrowers”) are party to a Loan and Security Agreement with eCapital, as successor in interest to Gerber Finance, Inc. (as amended, the “Star Loan Agreement”), which provides for a credit facility with borrowing availability of up to $2.5 million, bearing interest at the prime rate plus 3.5% per annum, and matures on January 31, 2025, unless terminated in accordance with the terms therein (the “Star Loan”). The following table presents the Star Loan balance, net of unamortized debt issuance costs as of March 31, 2023 (in thousands): March 31, 2023 Amount eCapital - Star Loan Principal $ 770 Unamortized debt issuance costs (61) eCapital - Star Loan Principal, net $ 709 The Star Loan, as amended, requires monthly payments of principal of $33 thousand plus interest at the prime rate plus 3% per annum through the earlier of maturity in January 2025 or the termination, maturity or repayment of any Obligations held with eCapital (as amended in the fourth amendment to the Star Loan Agreement). The Star Loan is secured by the assets of SRE, 947 Waterford Road, LLC, 300 Park Street, LLC and 56 Mechanic Falls Road, LLC and guaranteed by the Company. The Star loan is subject to certain annual financial covenants. The financial covenants under the Star Loan Agreement include maintenance of a Debt Service Coverage Ratio of not less than 1:00 to 1:00, as defined in the Star Loan Agreement. The occurrence of any event of default under the Star Loan Agreement may result in the obligations of the Star Borrowers becoming immediately due and payable. As of December 31, 2022, no event of default was deemed to have occurred and the Star Borrowers were in compliance with the annual financial covenants under the Star Loan Agreement measured as of December 31, 2022. The outstanding balance is classified as a short-term obligation as a result of the acceleration clauses within the EBGL and KBS credit facility and the cross-default provisions.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies In the normal course of business, we have been and will likely continue to be subject to other litigation or administrative proceedings incidental to our business, such as claims related to compliance with regulatory standards, customer disputes, employment practices, wage and hour disputes, product liability, professional liability, malpractice liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters and currently do not expect that the resolution of these matters will have a material adverse effect on our financial position or results of operations. The outcome of litigation and the amount or range of potential loss at particular points in time may be difficult to ascertain. Among other things, uncertainties can include how trial and appellate courts will apply the law and interpret facts, as well as the contractual and statutory obligations of other indemnifying and insuring parties. The estimated range of reasonably possible losses, and their effect on our financial position is based upon currently available information and is subject to significant judgment and a variety of assumptions, as well as known and unknown uncertainties.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We provide for income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of differences between the tax basis of assets or liabilities and their carrying amounts in the financial statements. We provide a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefit. We calculate the valuation allowance in accordance with the authoritative guidance relating to income taxes, which requires an assessment of both positive and negative evidence regarding the realizability of these deferred tax assets, when measuring the need for a valuation allowance. Significant judgment is required in determining any valuation allowance against deferred tax assets. We continue to record a full valuation allowance against our deferred tax assets and intend to maintain a valuation allowance until sufficient positive evidence exists to support its reversal. Intraperiod tax allocation rules require us to allocate our provision for income taxes between continuing operations and other categories of comprehensive income, such as discontinued operations. For the three months ended March 31, 2023, we recorded no income tax expense. For the three months ended March 31, 2022, we recorded $950 thousand income tax expense. The tax expense for the three months ended March 31, 2022 primarily relates to a January 2022 ownership change under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”) which required us to establish an additional valuation allowance on net operating losses that the Company cannot utilize in the future. As of March 31, 2023, we had unrecognized tax benefits of approximately $2.4 million related to uncertain tax positions. Included in the unrecognized tax benefits were $2.0 million of tax benefits that, if recognized, would reduce our annual effective tax rate, subject to the valuation allowance.

Segments

Segments	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segments	Segments Our reportable segments are based upon our internal organizational structure; the manner in which our operations are managed; the criteria used by our Chief Executive Officer, who is our Chief Operating Decision Maker (“CODM”), to evaluate segment performance; the availability of separate financial information; and overall materiality considerations. Prior to the sale of our Healthcare business on May 4, 2023, our three business divisions were organized into the following three reportable segments to reflect the manner in which our CODM assesses performance and allocates resources: 1. Healthcare 2. Construction 3. Investments Segment information for three months ended March 31, 2023 and 2022 is as follows (in thousands): Three Months Ended March 31, 2023 2022 Revenue by segment: Healthcare $ 13,359 $ 13,418 Construction 12,346 11,631 Investments 158 158 Intersegment elimination (158) (158) Consolidated revenue $ 25,705 $ 25,049 Gross profit (loss) by segment: Healthcare $ 3,327 $ 3,176 Construction 4,329 1,586 Investments 95 59 Intersegment elimination (158) (158) Consolidated gross profit $ 7,593 $ 4,663 Income (loss) from operations by segment: Healthcare $ 579 $ 78 Construction 1,782 (759) Investments (19) 59 Corporate, eliminations and other (1,612) (1,933) Segment income (loss) from operations $ 730 $ (2,555) Depreciation and amortization by segment: Healthcare $ 272 $ 315 Construction 505 487 Investments 63 99 Star Equity corporate 4 — Total depreciation and amortization $ 844 $ 901

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party TransactionsStar Equity Holdings, Inc.On December 10, 2021, the Company entered into a securities purchase agreement with its Executive Chairman, Jeffrey E. Eberwein, relating to the issuance and sale of 650,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $3.25 per share pursuant to a private placement. As of March 31, 2023, Mr. Eberwein owned 2,983,685 shares of Common Stock, representing approximately 19.64% of our outstanding Common Stock. In addition, as of March 31, 2023, Mr. Eberwein owned 1,222,458 shares of Series A Preferred Stock.

Perpetual Preferred Stock

Perpetual Preferred Stock	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Perpetual Preferred Stock	Perpetual Preferred Stock Holders of shares of our Series A Preferred Stock are entitled to receive, when, as and if, authorized by the Company’s board of directors (or a duly authorized committee of the Company’s board of directors) and declared by the Company out of funds legally available for the payment of dividends, preferential cumulative cash dividends at the rate of 10.0% per annum of the liquidation preference of $10.00 per share. Dividends are payable quarterly, in arrears, by the last calendar day of March, June, September and December to holders of record at the close of business on the first day of each payment month. The Series A Preferred Stock is not convertible and does not have any voting rights, except when dividends are in arrears for six or more consecutive quarters, then the holders of those shares together with holders of all other series of preferred stock equal in rank will be entitled to vote separately as a class for the election of two additional directors to board of directors, until all dividends accumulated on such shares of Series A Preferred Stock for the past dividend periods and the dividend for the current dividend period shall have been fully paid or declared and a sum sufficient for the payment thereof set apart for payment. Under change of control or other conditions, the Series A Preferred Stock may be subject to redemption. The Company may redeem the Series A Preferred Stock upon the occurrence of a change of control, subject to certain conditions. The Company may also voluntarily redeem some or all of the Series A Preferred Stock on or after September 10, 2024. On February 17, 2023, our board of directors declared a cash dividend to holders of our Series A Preferred Stock of $0.25 per share, for an aggregate amount of approximately $0.5 million. The record date for this dividend was March 1, 2023, and the payment date was March 10, 2023. As of March 31, 2023, we have no preferred dividends in arrears. On June 2, 2021, the board of directors adopted a tax benefit preservation plan in the form of a Section 382 Rights Agreement (the “382 Agreement”). The 382 Agreement is intended to diminish the risk that our ability to use our net operating loss carryforwards to reduce future federal income tax obligations may become substantially limited due to an “ownership change,” as defined in Section 382 of the Code. The board of directors authorized and declared a dividend distribution of one right for each outstanding share of common stock, par value $0.0001 per share, to stockholders of record as of the close of business on June 14, 2021. Each right entitles the registered holder to purchase from the one one-thousandth of a share of Series C Participating Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock”), at an exercise price of $12.00 per one one-thousandth of a share of Series C Preferred Stock, subject to adjustment. The rights will become exercisable following (i) 10 days after a public announcement that a person or group has become an Acquiring Person (as defined in the 382 Agreement); and (ii) 10 business days (or a later date determined by the board of directors) after a person or group begins a tender or an exchange offer that, if completed, would result in that person or group becoming an Acquiring Person. In addition, upon the occurrence of certain events, the exercise price of the rights would be adjusted and holders of the rights (other than rights owned by an acquiring person or group) would be entitled to purchase common stock at approximately half of market value. Given the potential adjustment of the exercise price of the rights, the rights could cause substantial dilution to a person or group that acquires 4.99% or more of common stock on terms not approved by the board of directors. No rights were exercisable at March 31, 2023. There is no impact to financial results as a result of the adoption of the 382 Agreement for the three months ended March 31, 2023.

Equity Transactions

Equity Transactions	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Equity Transactions	Equity Transactions On January 24, 2022, we closed an underwritten public offering (the “2022 Public Offering”) pursuant to an underwriting agreement with Maxim Group LLC (“Maxim”), as representative of the underwriters. Through the 2022 Public Offering, we issued and sold (A)(i) 9,175,000 shares of the Company’s Common Stock, (ii) an aggregate of 325,000 pre-funded warrants to purchase up to an aggregate of 325,000 shares of Common Stock, and (iii) an aggregate of 9,500,000 common stock purchase warrants (the “Firm Purchase Warrants”) to purchase up to 9,500,000 shares of Common Stock and (B) at the election of Maxim, (i) up to an additional 1,425,000 shares of Common Stock and/or (ii) up to an additional 1,425,000 shares of common stock purchase warrants (the “Option Purchase Warrants”, and together with the Firm Purchase Warrants, the “Warrants”). Maxim partially exercised its over-allotment option for the purchase of 1,425,000 Warrants for a price of $0.01 per Warrant. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one common warrant to purchase one share of common stock at a price of $1.50 per share and common warrant. Gross proceeds, before deducting underwriting discounts and offering expenses and excluding any proceeds we may receive upon exercise of the Warrants, were $14.3 million and net proceeds were $12.7 million. In addition, as part of the 2022 Public Offering, the Company issued to Maxim 237,500 common stock purchase warrants (the “Underwriter’s Warrants”) to purchase up to 237,500 shares of Common Stock at an exercise price of $1.65 per common warrant. The Underwriter’s Warrants have an initial exercise date beginning July 19, 2022. As of March 31, 2023, of the warrants issued through the public offering we closed on May 28, 2020 (the “2020 Public Offering”), 1.0 million warrants were exercised and 1.4 million warrants remained outstanding, which represents 0.7 million shares of common stock equivalents, at an exercise price of $2.25. As of March 31, 2023, of the Warrants issued through the 2022 Public Offering, there were 10.9 million Warrants and 0.3 million prefunded warrants outstanding at an exercise price of $1.50 and $0.01, respectively. The Underwriter’s Warrants have not been exercised.

Preferred Stock Rights

Preferred Stock Rights	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Preferred Stock Rights	Perpetual Preferred Stock Holders of shares of our Series A Preferred Stock are entitled to receive, when, as and if, authorized by the Company’s board of directors (or a duly authorized committee of the Company’s board of directors) and declared by the Company out of funds legally available for the payment of dividends, preferential cumulative cash dividends at the rate of 10.0% per annum of the liquidation preference of $10.00 per share. Dividends are payable quarterly, in arrears, by the last calendar day of March, June, September and December to holders of record at the close of business on the first day of each payment month. The Series A Preferred Stock is not convertible and does not have any voting rights, except when dividends are in arrears for six or more consecutive quarters, then the holders of those shares together with holders of all other series of preferred stock equal in rank will be entitled to vote separately as a class for the election of two additional directors to board of directors, until all dividends accumulated on such shares of Series A Preferred Stock for the past dividend periods and the dividend for the current dividend period shall have been fully paid or declared and a sum sufficient for the payment thereof set apart for payment. Under change of control or other conditions, the Series A Preferred Stock may be subject to redemption. The Company may redeem the Series A Preferred Stock upon the occurrence of a change of control, subject to certain conditions. The Company may also voluntarily redeem some or all of the Series A Preferred Stock on or after September 10, 2024. On February 17, 2023, our board of directors declared a cash dividend to holders of our Series A Preferred Stock of $0.25 per share, for an aggregate amount of approximately $0.5 million. The record date for this dividend was March 1, 2023, and the payment date was March 10, 2023. As of March 31, 2023, we have no preferred dividends in arrears. On June 2, 2021, the board of directors adopted a tax benefit preservation plan in the form of a Section 382 Rights Agreement (the “382 Agreement”). The 382 Agreement is intended to diminish the risk that our ability to use our net operating loss carryforwards to reduce future federal income tax obligations may become substantially limited due to an “ownership change,” as defined in Section 382 of the Code. The board of directors authorized and declared a dividend distribution of one right for each outstanding share of common stock, par value $0.0001 per share, to stockholders of record as of the close of business on June 14, 2021. Each right entitles the registered holder to purchase from the one one-thousandth of a share of Series C Participating Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock”), at an exercise price of $12.00 per one one-thousandth of a share of Series C Preferred Stock, subject to adjustment. The rights will become exercisable following (i) 10 days after a public announcement that a person or group has become an Acquiring Person (as defined in the 382 Agreement); and (ii) 10 business days (or a later date determined by the board of directors) after a person or group begins a tender or an exchange offer that, if completed, would result in that person or group becoming an Acquiring Person. In addition, upon the occurrence of certain events, the exercise price of the rights would be adjusted and holders of the rights (other than rights owned by an acquiring person or group) would be entitled to purchase common stock at approximately half of market value. Given the potential adjustment of the exercise price of the rights, the rights could cause substantial dilution to a person or group that acquires 4.99% or more of common stock on terms not approved by the board of directors. No rights were exercisable at March 31, 2023. There is no impact to financial results as a result of the adoption of the 382 Agreement for the three months ended March 31, 2023.

Variable Interest Entity

Variable Interest Entity	3 Months Ended
	Mar. 31, 2023
Variable Interest Entity, Not Primary Beneficiary, Disclosures [Abstract]
Variable Interest Entity	Variable Interest Entity VIE in which we are not the Primary Beneficiary We have an investment in a variable interest entity (“VIE”) of $0.3 million, recorded in Other Assets, in which we are not the primary beneficiary. This VIE is a small private company that is primarily involved in research related to new heart imaging technologies. We have determined that the governance structures of this entity do not allow us to direct the activities that would significantly affect its economic performance. Therefore, we are not the primary beneficiary, and the results of operations and financial position of the VIE are not included in our condensed consolidated financial statements. We account for this investment as non-marketable equity securities which is valued at cost less impairment.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On May 4, 2023, the Company entered into a Stock Purchase and Contribution Agreement (the “Purchase Agreement”), dated as of May 4, 2023 (the “Closing Date”), by and among the Company, Digirad Health Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Digirad Health”), TTG Imaging Solutions, LLC., a Pennsylvania limited liability company (the “Buyer”), and the Buyer’s Parent, Insignia TTG Parent LLC, a Delaware limited liability company (the “Parent”). Pursuant to the Purchase Agreement, (i) the Buyer purchased 85% of the issued and outstanding shares of Digirad Health, on the terms and subject to the conditions set forth therein and (ii) the Company contributed to Parent 15% of the issued and outstanding shares of stock of Digirad Health (the “Contributed Shares”) in exchange for New Units (as defined in the Purchase Agreement) of Parent (the “Transaction”). The total aggregate consideration payable to the Company for the Transaction is $40 million, comprised of $27 million in cash, a $7 million promissory note, and $6 million of New Units in the Parent. The Company completed the sale of Digirad Health simultaneously with entering into the Purchase Agreement. The Purchase Agreement contains representations, warranties and covenants of the Company and Digirad Health that are customary for a transaction of this nature. The Purchase Agreement also contains indemnification obligations of the parties thereto. Pursuant to the Purchase Agreement, the Company has made a 336(e) election under the Code. In accordance with GAAP (ASC 205-20-45-1E), the Company evaluated the requirements needed to record the Digirad Health assets and liabilities as held-for-sale noting that for Q1 2023 “held and used” accounting was appropriate. Concurrent with the Transaction, the Company terminated its debt with Webster by paying in full all amounts due at the Closing Date of the Transaction, which approximated $8.7 million. As a result of the Transaction, the Company no longer has a Healthcare division as of May 4, 2023. On April 28, 2023, the Company gave notice to eCapital that it would not be renewing its credit facilities upon the expiry of the current extension to June 30, 2023. The Company paid in full all amounts outstanding on May 9, 2023 totaling approximately $0.8 million. The Company cancelled all eCapital credit facilities on May 9, 2023.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (the “SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally Accepted Accounting Principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed Consolidated Balance Sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2022, filed with the SEC on Form 10-K on March 15, 2023, include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows, and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and disclosures made in the accompanying notes to the condensed consolidated financial statements. Significant estimates and judgments include those related to inventory, revenue recognition, lease accounting, fair value measurements (including contingent considerations), litigation and contingent liabilities, variable interest entities, intangible assets and goodwill valuations, equity classification and transactions, and income taxes. Actual results could materially differ from those estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents and accounts receivable. We limit our exposure to credit loss by generally placing cash in high credit quality financial institutions. Cash balances are maintained primarily at major financial institutions in the United States, a portion of which exceed the regulatory limit of $250,000 insured by the Federal Deposit Insurance Corporation (FDIC). We have not experienced any credit losses associated with our cash balances. Additionally, we have established guidelines regarding diversification of our investments and their maturities, which are designed to maintain principal and maximize liquidity. As of March 31, 2023 we have $4.4 million of cash in excess of FDIC insured limits
New Accounting Standards To Be Adopted	New Accounting Standards To Be Adopted No new accounting standards were issued in the quarter ended March 31, 2023 that are expected to have a material impact on our financial statements.
Commitments and Contingencies	In the normal course of business, we have been and will likely continue to be subject to other litigation or administrative proceedings incidental to our business, such as claims related to compliance with regulatory standards, customer disputes, employment practices, wage and hour disputes, product liability, professional liability, malpractice liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters and currently do not expect that the resolution of these matters will have a material adverse effect on our financial position or results of operations. The outcome of litigation and the amount or range of potential loss at particular points in time may be difficult to ascertain. Among other things, uncertainties can include how trial and appellate courts will apply the law and interpret facts, as well as the contractual and statutory obligations of other indemnifying and insuring parties. The estimated range of reasonably possible losses, and their effect on our financial position is based upon currently available information and is subject to significant judgment and a variety of assumptions, as well as known and unknown uncertainties.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables present our revenues for the three months ended March 31, 2023 and 2022, disaggregated by major source (in thousands): Three Months Ended March 31, 2023 Healthcare Construction Total Major Goods/Service Lines Mobile Imaging (1) $ 10,323 $ — $ 10,323 Camera Sales 952 — 952 Camera Support 1,899 — 1,899 Healthcare Revenue from Contracts with Customers 13,174 — 13,174 Lease Income 185 — 185 Construction Revenue from Contracts with Customers — 12,346 12,346 Total Revenues $ 13,359 $ 12,346 $ 25,705 Timing of Revenue Recognition Services and goods transferred over time $ 10,545 $ — $ 10,545 Services and goods transferred at a point in time 2,814 12,346 15,160 Total Revenues $ 13,359 $ 12,346 $ 25,705 Three Months Ended March 31, 2022 Healthcare Construction Total Major Goods/Service Lines Mobile Imaging (1) $ 10,518 $ — $ 10,518 Camera Sales 1,132 — 1,132 Camera Support 1,679 — 1,679 Healthcare Revenue from Contracts with Customers 13,329 — 13,329 Lease Income 89 — 89 Construction Revenue from Contracts with Customers — 11,631 11,631 Total Revenues $ 13,418 $ 11,631 $ 25,049 Timing of Revenue Recognition Services and goods transferred over time $ 10,854 $ 1,897 $ 12,751 Services and goods transferred at a point in time 2,564 9,734 12,298 Total Revenues $ 13,418 $ 11,631 $ 25,049
Changes in Deferred Revenue	Changes in deferred revenue for the three months ended March 31, 2023, is as follows (in thousands): Balance at December 31, 2022 $ 3,675 Revenue recognized that was included in balance at beginning of the year (1,790) Deferred revenue, net, related to contracts entered into during the year 1,298 Balance at March 31, 2023 $ 3,183

Basic and Diluted Net Income _2

Basic and Diluted Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Reconciliation of Shares Used to Compute Basic and Diluted Net Income (Loss) Per Share	The following table sets forth the reconciliation of shares used to compute basic and diluted net income (loss) per share for the periods indicated (in thousands): Three Months Ended March 31, 2023 2022 Numerator: Net income (loss) 435 (3,701) Deemed dividend on Series A perpetual preferred stock (479) (479) Net income (loss) attributable to common shareholders $ (44) $ (4,180) Denominator: Weighted average common shares outstanding 15,191 12,434 Weighted average prefunded warrants outstanding 325 235 Weighted average shares outstanding - basic 15,516 12,669 Dilutive potential common shares: Restricted stock units 140 — Weighted average shares outstanding - diluted 15,656 12,669 Net income (loss) per share Basic $ 0.03 $ (0.29) Diluted $ 0.03 $ (0.29) Net income (loss) per share, attributable to common shareholders Basic $ — $ (0.33) Diluted $ — $ (0.33) *Earnings per share may not add due to rounding
Schedule of Antidilutive Securities Excluded from Computation of Net Income (Loss) Per Share	The computation of diluted earnings per share excludes stock options, RSUs, and stock warrants that are anti-dilutive. The following common stock equivalents were anti-dilutive (in thousands): Three Months Ended March 31, 2023 2022 Stock options 2 6 Restricted stock units 80 271 Stock warrants 11,865 9,361 Total 11,947 9,638

Supplementary Balance Sheet I_2

Supplementary Balance Sheet Information (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	The components of inventories are as follows (in thousands): March 31, 2023 December 31, 2022 Raw materials $ 5,609 $ 6,330 Work-in-process 2,772 2,567 Finished goods 1,886 1,946 Total inventories 10,267 10,843 Less reserve for excess and obsolete inventories (224) (216) Total inventories, net $ 10,043 $ 10,627
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): March 31, 2023 December 31, 2022 Land $ 805 $ 805 Buildings and leasehold improvements 4,843 4,843 Machinery and equipment 24,398 24,648 Computer hardware and software 2,486 2,465 Gross property and equipment 32,532 32,761 Accumulated depreciation (24,430) (24,413) Total property and equipment, net $ 8,102 $ 8,348
Schedule of Product Warranty Liability	The activities related to our warranty reserve for the period ended March 31, 2023 and year ended December 31, 2022 are as follows (in thousands): March 31, 2023 December 31, 2022 Balance at the beginning of year $ 291 $ 569 Charges to cost of revenues 85 177 Applied to liability (86) (455) Balance at the end of period $ 290 $ 291

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of Lease Cost and Other Information	The components of lease expense are as follows (in thousands): Three Months Ended March 31, 2023 2022 Operating lease cost $ 390 $ 396 Finance lease cost: Amortization of finance lease assets $ 116 $ 123 Interest on finance lease liabilities 11 17 Total finance lease cost $ 127 $ 140 Supplemental cash flow information related to leases from continuing operations was as follows (in thousands): Three Months Ended March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 349 $ 199 Operating cash flows from finance leases $ 11 $ 17 Financing cash flows from finance leases $ 139 $ 157 Right-of-use assets obtained in exchange for lease obligations Operating leases $ — $ 1,229
Schedule of Balance Sheet Information	Supplemental balance sheet information related to leases was as follows (in thousands): March 31, December 31, Weighted average remaining lease term (in years) Operating leases 3.5 3.7 Finance leases 2.1 2.3 Weighted average discount rate Operating leases 4.68 % 4.66 % Finance leases 5.98 % 5.98 %
Schedule of Future Minimum Finance Lease Payments	The future minimum lease payments due under both non-cancelable operating leases and finance leases having initial or remaining lease terms in excess of one year as of March 31, 2023 were as follows (in thousands): Operating Leases Finance Leases 2023 (excludes the three months ended March 31, 2023) $ 1,146 $ 292 2024 1,392 266 2025 918 103 2026 591 16 2027 155 1 2028 and thereafter 206 — Total future minimum lease payments 4,408 678 Less amounts representing interest 288 30 Present value of lease obligations $ 4,120 $ 648
Schedule of Future Minimum Operating Lease Payments, Lessee	The future minimum lease payments due under both non-cancelable operating leases and finance leases having initial or remaining lease terms in excess of one year as of March 31, 2023 were as follows (in thousands): Operating Leases Finance Leases 2023 (excludes the three months ended March 31, 2023) $ 1,146 $ 292 2024 1,392 266 2025 918 103 2026 591 16 2027 155 1 2028 and thereafter 206 — Total future minimum lease payments 4,408 678 Less amounts representing interest 288 30 Present value of lease obligations $ 4,120 $ 648

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Financial Assets Measured at Fair Value on a Recurring Basis	The following table presents information about our financial assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2023 and December 31, 2022 (in thousands): Fair Value as of March 31, 2023 Level 1 Level 2 Level 3 Total Assets (Liabilities): Equity securities $ 3,577 $ — $ — $ 3,577 Lumber derivative contracts (62) — — (62) Total $ 3,515 $ — $ — $ 3,515 Fair Value as of December 31, 2022 Level 1 Level 2 Level 3 Total Assets (Liabilities): Equity securities $ 3,490 $ — $ — $ 3,490 Lumber derivative contracts (104) — — (104) Total $ 3,386 $ — $ — $ 3,386
Derivative Instruments, Gain (Loss)	Gains and losses from lumber derivative contracts are recorded in cost of goods sold of the condensed Consolidated Statements of Operations and included the following for the three months ended March 31, 2023 and 2022, respectively: March 31, 2023 March 31, 2022 Unrealized gain (loss) on lumber derivatives $ (43) $ 676 Realized gain (loss) on lumber derivatives 89 (448) Total gain (loss) on lumber derivatives $ 46 $ 228

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Short-term Debt	A summary of debt as of March 31, 2023 and December 31, 2022 is as follows (dollars in thousands): March 31, 2023 December 31, 2022 Amount Weighted-Average Interest Rate Amount Weighted-Average Interest Rate Revolving Credit Facility - eCapital KBS $ — 10.75% $ — 10.25% Revolving Credit Facility - eCapital EBGL — 10.75% 2,592 10.25% Revolving Credit Facility - Webster 7,685 7.36% 8,299 6.89% Total Short-term Revolving Credit Facilities $ 7,685 7.36% $ 10,891 7.69% eCapital - Star Loan Principal, net $ 709 11.00% $ 791 10.50% Short Term Loan $ 709 11.00% $ 791 10.50% Total Short-term debt $ 8,394 7.67% $ 11,682 7.88% The following table presents the Star Loan balance, net of unamortized debt issuance costs as of March 31, 2023 (in thousands): March 31, 2023 Amount eCapital - Star Loan Principal $ 770 Unamortized debt issuance costs (61) eCapital - Star Loan Principal, net $ 709

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Segment information for three months ended March 31, 2023 and 2022 is as follows (in thousands): Three Months Ended March 31, 2023 2022 Revenue by segment: Healthcare $ 13,359 $ 13,418 Construction 12,346 11,631 Investments 158 158 Intersegment elimination (158) (158) Consolidated revenue $ 25,705 $ 25,049 Gross profit (loss) by segment: Healthcare $ 3,327 $ 3,176 Construction 4,329 1,586 Investments 95 59 Intersegment elimination (158) (158) Consolidated gross profit $ 7,593 $ 4,663 Income (loss) from operations by segment: Healthcare $ 579 $ 78 Construction 1,782 (759) Investments (19) 59 Corporate, eliminations and other (1,612) (1,933) Segment income (loss) from operations $ 730 $ (2,555) Depreciation and amortization by segment: Healthcare $ 272 $ 315 Construction 505 487 Investments 63 99 Star Equity corporate 4 — Total depreciation and amortization $ 844 $ 901

Basis of Presentation and Sig_3

Basis of Presentation and Significant Policies - Narrative (Details) $ / shares in Units, $ in Thousands			3 Months Ended
	May 04, 2023 USD ($)	Mar. 31, 2021 segment	Mar. 31, 2023 USD ($) $ / shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of operating segments | segment		2
Net (loss) income			$ 435	$ (3,701)
Net cash provided by (used in) operating activities			5,132	(636)
Cash and cash equivalents			5,655	$ 15,035	$ 4,665
Investments in equity securities			3,577		$ 3,490
Cash, FDIC insured amount			250
Cash in excess of FDIC limit			$ 4,400
Preferred stock, liquidation preference per share (in usd per share) | $ / shares			$ 10
Subsequent Event | TTG Imaging Solutions, LLC And Insignia Parent, LLC | Digirad Health Inc.
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash proceeds from sale of equity	$ 27,000

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ in Thousands	3 Months Ended	4 Months Ended
	Mar. 31, 2023 USD ($) segment	May 04, 2023 segment	Dec. 31, 2022 USD ($)
Disaggregation of Revenue [Line Items]
Number of reportable segments	3
Non-current deferred revenue | $	$ 257		$ 299
Subsequent Event
Disaggregation of Revenue [Line Items]
Number of reportable segments		3
Minimum
Disaggregation of Revenue [Line Items]
Deferred revenue, recognition period	2 years
Maximum
Disaggregation of Revenue [Line Items]
Deferred revenue, recognition period	4 years

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Lease Income	$ 185	$ 89
Total Revenues	25,705	25,049
Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	10,545	12,751
Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	15,160	12,298
Mobile Imaging
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	10,323	10,518
Camera Sales
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	952	1,132
Camera Support
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	1,899	1,679
Healthcare
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	13,174	13,329
Total Revenues	13,359	13,418
Construction Revenue from Contracts with Customers
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	12,346	11,631
Total Revenues	12,346	11,631
Healthcare
Disaggregation of Revenue [Line Items]
Lease Income	185	89
Total Revenues	13,359	13,418
Healthcare | Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	10,545	10,854
Healthcare | Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	2,814	2,564
Healthcare | Mobile Imaging
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	10,323	10,518
Healthcare | Camera Sales
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	952	1,132
Healthcare | Camera Support
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	1,899	1,679
Healthcare | Healthcare
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	13,174	13,329
Healthcare | Construction Revenue from Contracts with Customers
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	0	0
Construction
Disaggregation of Revenue [Line Items]
Lease Income	0	0
Total Revenues	12,346	11,631
Construction | Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	0	1,897
Construction | Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	12,346	9,734
Construction | Mobile Imaging
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	0	0
Construction | Camera Sales
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	0	0
Construction | Camera Support
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	0	0
Construction | Healthcare
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	0	0
Construction | Construction Revenue from Contracts with Customers
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 12,346	$ 11,631

Revenue - Schedule of Changes i

Revenue - Schedule of Changes in Deferred Revenue (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Deferred Revenue
Beginning balance	$ 3,675
Revenue recognized that was included in balance at beginning of the year	(1,790)
Deferred revenue, net, related to contracts entered into during the year	1,298
Ending balance	$ 3,183

Basic and Diluted Net Income _3

Basic and Diluted Net Income (Loss) Per Share - Reconciliation of Shares Used to Compute Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator:
Net income (loss)	$ 435	$ (3,701)
Deemed dividend on Series A perpetual preferred stock	(479)	(479)
Net income (loss) attributable to common shareholders	(44)	(4,180)
Net income (loss) attributable to common shareholders	$ (44)	$ (4,180)
Denominator:
Weighted average common shares outstanding (in shares)	15,191	12,434
Weighted average prefunded warrants outstanding (in shares)	325	235
Weighted-average shares outstanding - basic (in shares)	15,516	12,669
Weighted-average common shares outstanding - diluted (in shares)	15,656	12,669
Net income (loss) per share
Net income (loss) per share - basic (in usd per share)	$ 0.03	$ (0.29)
Net income (loss) per share - diluted (in usd per share)	0.03	(0.29)
Net income (loss) per share, attributable to common shareholders— basic (in usd per share)	0	(0.33)
Net income (loss) per share, attributable to common shareholders— diluted (in usd per share)	$ 0	$ (0.33)
Restricted stock units
Denominator:
Dilutive potential common shares (in shares)	140	0

Basic and Diluted Net Income _4

Basic and Diluted Net Income (Loss) Per Share - Anti-dilutive Shares (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	11,947	9,638
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	2	6
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	80	271
Stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	11,865	9,361

Supplementary Balance Sheet I_3

Supplementary Balance Sheet Information - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 5,609	$ 6,330
Work-in-process	2,772	2,567
Finished goods	1,886	1,946
Total inventories	10,267	10,843
Less reserve for excess and obsolete inventories	(224)	(216)
Total inventories, net	$ 10,043	$ 10,627

Supplementary Balance Sheet I_4

Supplementary Balance Sheet Information - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 32,532	$ 32,761
Accumulated depreciation	(24,430)	(24,413)
Total property and equipment, net	8,102	8,348
Land
Property, Plant and Equipment [Line Items]
Gross property and equipment	805	805
Buildings and leasehold improvements
Property, Plant and Equipment [Line Items]
Gross property and equipment	4,843	4,843
Machinery and equipment
Property, Plant and Equipment [Line Items]
Gross property and equipment	24,398	24,648
Computer hardware and software
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,486	$ 2,465

Supplementary Balance Sheet I_5

Supplementary Balance Sheet Information - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 32,532	$ 32,761
Building And Construction
Property, Plant and Equipment [Line Items]
Standard warranty period	12 months
EBGL
Property, Plant and Equipment [Line Items]
Standard warranty period	25 years
Land and Building
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 1,900

Supplementary Balance Sheet I_6

Supplementary Balance Sheet Information - Warranty Reserve (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at the beginning of year	$ 291	$ 569
Charges to cost of revenues	85	177
Applied to liability	(86)	(455)
Balance at the end of period	$ 290	$ 291

Leases - Narrative (Details)

Leases - Narrative (Details)	3 Months Ended
	Mar. 31, 2023
Lessee, Lease, Description [Line Items]
Option to terminate period (in years)	1 year
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term (in years)	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term (in years)	10 years

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Operating lease cost	$ 390	$ 396
Finance lease cost:
Amortization of finance lease assets	116	123
Interest on finance lease liabilities	11	17
Total finance lease cost	$ 127	$ 140

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$ 349	$ 199
Operating cash flows from finance leases	11	17
Financing cash flows from finance leases	139	157
Right-of-use assets obtained in exchange for lease obligations
Operating leases	$ 0	$ 1,229

Leases - Schedule of Suppleme_2

Leases - Schedule of Supplemental Balance Sheet Information (Details)	Mar. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease, weighted average remaining lease term (in years)	3 years 6 months	3 years 8 months 12 days
Financing leases, weighted average remaining lease term (in years)	2 years 1 month 6 days	2 years 3 months 18 days
Operating leases, weighted average discount rate (percent)	4.68%	4.66%
Financing leases, weighted average discount rate (percent)	5.98%	5.98%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments, Lessee (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Operating Leases
2023 (excludes the three months ended March 31, 2023)	$ 1,146
2024	1,392
2025	918
2026	591
2027000	155
2028 and thereafter	206
Total future minimum lease payments	4,408
Less amounts representing interest	288
Present value of lease obligations	4,120
Finance Leases
2023 (excludes the three months ended March 31, 2023)	292
2024	266
2025	103
2026	16
2027000	1
2028 and thereafter	0
Total future minimum lease payments	678
Less amounts representing interest	30
Present value of lease obligations	$ 648

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	$ 3,577	$ 3,490
Lumber derivative contracts	(62)	(104)
Total	3,515	3,386
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	3,577	3,490
Lumber derivative contracts	(62)	(104)
Total	3,515	3,386
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Lumber derivative contracts	0	0
Total	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Lumber derivative contracts	0	0
Total	$ 0	$ 0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) boardFeet in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($) boardFeet derivative	Mar. 31, 2022 USD ($)	Dec. 31, 2022 boardFeet derivative
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities, unrealized gain	$ 2	$ 92
Long
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, nonmonetary notional amount (board feet) | boardFeet	5,500		550
Number of derivative instruments held | derivative	50		5
Commodity Contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loss on derivatives	$ 46	$ 228

Fair Value Measurements - Deriv

Fair Value Measurements - Derivative Instruments, Gain (Loss) (Details) - Commodity Contract - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized gain (loss) on lumber derivatives	$ (43)	$ 676
Realized gain (loss) on lumber derivatives	89	(448)
Total gain (loss) on lumber derivatives	$ 46	$ 228

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total Short-term debt	$ 8,394	$ 11,682
Weighted-Average Interest Rate	7.67%	7.88%
eCapital - Star Loan Principal, net
Debt Instrument [Line Items]
Total Short-term Revolving Credit Facilities	$ 709	$ 791
Weighted-Average Interest Rate	11%	10.50%
Short Term Loan
Debt Instrument [Line Items]
Total Short-term Revolving Credit Facilities	$ 709	$ 791
Weighted-Average Interest Rate	11%	10.50%
Revolving Credit Facility | Revolving Credit Facility - eCapital KBS
Debt Instrument [Line Items]
Total Short-term Revolving Credit Facilities	$ 0	$ 0
Weighted-Average Interest Rate	10.75%	10.25%
Revolving Credit Facility | Revolving Credit Facility - eCapital EBGL
Debt Instrument [Line Items]
Total Short-term Revolving Credit Facilities	$ 0	$ 2,592
Weighted-Average Interest Rate	10.75%	10.25%
Revolving Credit Facility | Revolving Credit Facility - Webster
Debt Instrument [Line Items]
Total Short-term Revolving Credit Facilities	$ 7,685	$ 8,299
Weighted-Average Interest Rate	7.36%	6.89%
Revolving Credit Facility | Total Short-term Revolving Credit Facilities
Debt Instrument [Line Items]
Total Short-term Revolving Credit Facilities	$ 7,685	$ 10,891
Weighted-Average Interest Rate	7.36%	7.69%

Debt - Webster Credit Facility

Debt - Webster Credit Facility (Details) - USD ($) $ in Millions	Mar. 29, 2019	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Weighted average interest rate (percent)		7.67%	7.88%
Revolving Credit Facility | Revolving Credit Facility - Webster
Debt Instrument [Line Items]
Weighted average interest rate (percent)		7.36%	6.89%
Revolving Credit Facility | SNB | Line of Credit | Revolving Credit Facility - Webster
Debt Instrument [Line Items]
Debt term (in years)	5 years
Maximum borrowing capacity	$ 20
Letters of credit (not to exceed)	$ 0.5
Borrowing availability		$ 0.5
Revolving Credit Facility | SNB | Line of Credit | Revolving Credit Facility - Webster | Minimum
Debt Instrument [Line Items]
Fixed charge coverage ratio	1.25
Revolving Credit Facility | SNB | Line of Credit | Revolving Credit Facility - Webster | Maximum
Debt Instrument [Line Items]
Leverage ratio	3.50
Revolving Credit Facility | SNB | Line of Credit | Revolving Credit Facility - Webster | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Interest rate (percent)	2.50%
Basis spread (percent)	2.25%
Revolving Credit Facility | SNB | Letter of Credit
Debt Instrument [Line Items]
Letters of credit (not to exceed)		$ 0.1

Debt - eCapital Credit Faciliti

Debt - eCapital Credit Facilities (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022	Dec. 31, 2022
EBGL Loan Agreement
Debt Instrument [Line Items]
Debt covenant for income		$ 0	$ 1,000,000
Revolving Credit Facility | EBGL Loan Agreement | EBGL Credit Parties | Prime Rate
Debt Instrument [Line Items]
Basis spread (percent)	2.75%
Revolving Credit Facility | EBGL Loan Agreement | Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 4,000,000
Additional borrowing capacity	2,800,000
Revolving Credit Facility | eCapital KBS Loan Agreement | Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	4,000,000
Debt covenant for income		0	500,000
Additional borrowing capacity	$ 1,000,000
Debt covenant, minimum earnings before interest tax and depreciation		$ 0	$ 850,000
Revolving Credit Facility | eCapital KBS Loan Agreement | Line of Credit | Prime Rate
Debt Instrument [Line Items]
Stated rate (percent)	2.75%

Debt - Term Loans (Details)

Debt - Term Loans (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
eCapital - Star Loan Principal, net
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 2,500
eCapital - Star Loan Principal	770
Unamortized debt issuance costs	(61)
eCapital - Star Loan Principal, net	$ 709
eCapital - Star Loan Principal, net | Minimum
Debt Instrument [Line Items]
Debt service coverage ratio	1
eCapital - Star Loan Principal, net | Prime Rate
Debt Instrument [Line Items]
Basis spread (percent)	3.50%
Amended Star Loan Agreement
Debt Instrument [Line Items]
Debt instrument, monthly payment	$ 33
Amended Star Loan Agreement | Prime Rate
Debt Instrument [Line Items]
Basis spread (percent)	3%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 0	$ 950
Unrecognized tax benefits	2,400
Unrecognized tax benefits that would impact effective tax rate	$ 2,000

Segments - Narrative (Details)

Segments - Narrative (Details)	3 Months Ended
	Mar. 31, 2023 segment
Segment Reporting [Abstract]
Number of reportable segments	3

Segments - Schedule of Segment

Segments - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Consolidated revenue	$ 25,705	$ 25,049
Consolidated gross profit	7,593	4,663
Income (loss) from operations by segment	730	(2,555)
Segment income (loss) from operations	730	(2,555)
Total depreciation and amortization	844	901
Healthcare
Segment Reporting Information [Line Items]
Consolidated revenue	13,359	13,418
Total depreciation and amortization	272	315
Construction
Segment Reporting Information [Line Items]
Consolidated revenue	12,346	11,631
Total depreciation and amortization	505	487
Investments
Segment Reporting Information [Line Items]
Total depreciation and amortization	63	99
Operating Segments | Healthcare
Segment Reporting Information [Line Items]
Consolidated revenue	13,359	13,418
Consolidated gross profit	3,327	3,176
Income (loss) from operations by segment	579	78
Operating Segments | Construction
Segment Reporting Information [Line Items]
Consolidated revenue	12,346	11,631
Consolidated gross profit	4,329	1,586
Income (loss) from operations by segment	1,782	(759)
Operating Segments | Investments
Segment Reporting Information [Line Items]
Consolidated revenue	158	158
Consolidated gross profit	95	59
Income (loss) from operations by segment	(19)	59
Intersegment elimination
Segment Reporting Information [Line Items]
Consolidated revenue	(158)	(158)
Consolidated gross profit	(158)	(158)
Income (loss) from operations by segment	(1,612)	(1,933)
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total depreciation and amortization	$ 4	$ 0

Related Party Transaction (Deta

Related Party Transaction (Details) - $ / shares	Dec. 10, 2021	Mar. 31, 2023	Dec. 31, 2022	Jun. 14, 2021
Related Party Transaction [Line Items]
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, outstanding (in shares)		15,192,753	15,177,919
Series A Preferred Stock
Related Party Transaction [Line Items]
Preferred stock, outstanding (in shares)		1,915,637
Board of Directors Chairman | Digirad Corporation
Related Party Transaction [Line Items]
Common stock, outstanding (in shares)		2,983,685
Percentage of outstanding shares		19.64%
Board of Directors Chairman | Digirad Corporation | Series A Preferred Stock
Related Party Transaction [Line Items]
Preferred stock, outstanding (in shares)		1,222,458
Board of Directors Chairman | Private Placement
Related Party Transaction [Line Items]
Number of shares issued in transaction (in shares)	650,000
Price of stock sold (in usd per share)	$ 3.25

Perpetual Preferred Stock - Nar

Perpetual Preferred Stock - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended
	Feb. 17, 2023	Mar. 31, 2023	Mar. 31, 2022
Class of Stock [Line Items]
Preferred stock, dividend rate (in percent)		10%
Liquidation preference (in usd per share)		$ 10
Dividends declared per Series A perpetual preferred stock (in usd per share)	$ 0.25	$ 0.25	$ 0.25
Series A Cumulative Perpetual Preferred Stock
Class of Stock [Line Items]
Preferred stock dividends paid	$ 0.5

Equity Transactions (Details)

Equity Transactions (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended
	Jan. 24, 2022	Mar. 31, 2023
2022 Public Offering
Schedule of Equity Method Investments [Line Items]
Number of shares issued in transaction (in shares)	9,175,000
Number of warrants exercised (in shares)	1,425,000
Exercise price of warrants (in usd per share)	$ 0.01
Price of stock sold (in usd per share)	$ 1.50
Consideration received	$ 14.3
Net proceeds	$ 12.7
2022 Public Offering | Prefunded Warrant
Schedule of Equity Method Investments [Line Items]
Number of warrants issued in transaction (in shares)	325,000
Class of warrant or right, number of securities called by warrants or rights (in shares)	325,000
Exercise price of warrants (in usd per share)		$ 0.01
Warrants outstanding (in shares)		300,000
2022 Public Offering | Firm Purchase Warrants
Schedule of Equity Method Investments [Line Items]
Number of warrants issued in transaction (in shares)	9,500,000
Class of warrant or right, number of securities called by warrants or rights (in shares)	9,500,000
2022 Public Offering | Firm Purchase Warrants | Maxim Group LLC
Schedule of Equity Method Investments [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares)	237,500
Number of warrants exercised (in shares)	237,500
Exercise price of warrants (in usd per share)	$ 1.65
2022 Public Offering | Option Shares
Schedule of Equity Method Investments [Line Items]
Number of shares issued in transaction (in shares)	1,425,000
2022 Public Offering | Option Purchase Warrants
Schedule of Equity Method Investments [Line Items]
Number of warrants issued in transaction (in shares)	1,425,000
2022 Public Offering | Stock Warrants
Schedule of Equity Method Investments [Line Items]
Exercise price of warrants (in usd per share)		$ 1.50
Warrants outstanding (in shares)		10,900,000
2020 Public Offering
Schedule of Equity Method Investments [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares)		700,000
Number of warrants exercised (in shares)		1,000,000
Exercise price of warrants (in usd per share)		$ 2.25
Warrants outstanding (in shares)		1,400,000

Preferred Stock Rights (Details

Preferred Stock Rights (Details) - $ / shares	Mar. 31, 2023	Dec. 31, 2022	Dec. 10, 2021	Jun. 14, 2021
Class of Stock [Line Items]
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Number of days for stock rights to become exercisable (in days)				10 days
Acquisition of common stock, threshold (percent)				4.99%
Dividend rights exercisable (in shares)	0
Series C Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in usd per share)	$ 0.0001	$ 0.0001		$ 0.0001
Cash redemption price (in usd per share)				$ 12

Variable Interest Entity (Detai

Variable Interest Entity (Details) $ in Millions	Mar. 31, 2023 USD ($)
Variable Interest Entity, Not Primary Beneficiary, Disclosures [Abstract]
Other investments	$ 0.3

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event - USD ($) $ in Millions	May 09, 2023	May 04, 2023
Revolving Credit Facility | Line of Credit | Revolving Credit Facility - Webster | SNB
Subsequent Event [Line Items]
Extinguishment of debt		$ 8.7
Revolving Credit Facility | Line of Credit | Revolving Credit Facility - eCapital EBGL
Subsequent Event [Line Items]
Extinguishment of debt	$ 0.8
TTG Imaging Solutions, LLC And Insignia Parent, LLC | Digirad Health Inc.
Subsequent Event [Line Items]
Percentage of subsidiary stock sold		85%
Percentage of shares contributed		15%
Net proceeds		$ 40
Cash proceeds from sale of equity		27
Notes issued in sale transaction		7
Value of shares issued in transaction		$ 6